fbpx Skip to main content

MONDAY, Sept. 28, 2020 (HealthDay News) — Intrauterine exposure to maternal gestational diabetes is associated with increased cardiovascular disease risk and risk factors in offspring up to age 35 years, according to a study published online Sept. 28 in CMAJ, the journal of the Canadian Medical Association.

Laetitia Guillemette, Ph.D., from the Children’s Hospital Research Institute of Manitoba in Winnipeg, Canada, and colleagues conducted a cohort study of 293,546 offspring born between 1979 and 2005 and followed until March 2015 to examine the potential association between exposure to maternal diabetes and cardiovascular disease events.

The researchers found that during 3,628,576 person-years of follow-up, 0.9 percent of the offspring experienced a cardiovascular disease end point and 4.3 percent experienced a cardiovascular disease risk factor. The risk for cardiovascular disease end points was significantly increased in offspring exposed to gestational diabetes after propensity score matching (adjusted hazard ratio, 1.42; 95 percent confidence interval, 1.12 to 1.79); no significantly increased risk was seen with exposure to type 2 diabetes (adjusted hazard ratio, 1.40; 95 percent confidence interval, 0.98 to 2.01). For cardiovascular disease risk factors, a similar association was observed (gestational diabetes: adjusted hazard ratio, 1.92; 95 percent confidence interval, 1.75 to 2.11; type 2 diabetes: adjusted hazard ratio, 3.40; 95 percent confidence interval, 3.00 to 3.85).

“Screening children with in utero exposure to diabetes for cardiovascular disease risk factors might help to evaluate the future burden related to cardiovascular disease in the population,” the authors write.

Abstract/Full Text

You May Also Like::  SGLT2 Inhibitors for Transthyretin Amyloid Cardiomyopathy

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More